Charles Schwab
IMRX icon

Charles Schwab’s Immuneering IMRX Stock Holding History

Charles Schwab’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$838K Buy
167,901
+130,557
+350% +$660K ﹤0.01% 3056
2026
Q1 		$197K Buy
37,344
+15,000
+67% +$76.9K ﹤0.01% 3304
2025
Q4 		$147K Hold
22,344
– – ﹤0.01% 3372
2025
Q3 		$156K Buy
22,344
+10,344
+86% +$53.7K ﹤0.01% 3368
2025
Q2 		$40.4K Hold
12,000
– – ﹤0.01% 3462
2025
Q1 		$18.2K Buy
+12,000
New +$21.8K ﹤0.01% 3462
2024
Q2 		– Sell
-60,512
Closed -$175K – 3652
2024
Q1 		$175K Hold
60,512
– – ﹤0.01% 3254
2023
Q4 		$445K Hold
60,512
– – ﹤0.01% 3118
2023
Q3 		$465K Buy
60,512
+5,472
+10% +$50.3K ﹤0.01% 3062
2023
Q2 		$558K Buy
+55,040
New +$529K ﹤0.01% 2999
2022
Q2 		– Sell
-45,441
Closed -$295K – 3592
2022
Q1 		$295K Buy
45,441
+24,044
+112% +$231K ﹤0.01% 3217
2021
Q4 		$346K Buy
21,397
+1,161
+6% +$28.3K ﹤0.01% 3259
2021
Q3 		$538K Buy
+20,236
New +$544K ﹤0.01% 3124

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab's IMRX Position: Q2 2026 in Review

Charles Schwab increased its Immuneering (IMRX) stake by 350% in Q2 2026, buying an estimated $660K and bringing the position to 167,901 shares worth $838K. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Charles Schwab first reported a position in IMRX in Q3 2021 and has held it in 13 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Charles Schwab held 167,901 shares of Immuneering worth $838K as of Q2 2026.
  • Charles Schwab bought 130,557 Immuneering shares in Q2 2026, an estimated $660K.
  • Immuneering made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3056 holding.
  • Charles Schwab first reported a position in Immuneering in Q3 2021 and has held it in 13 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.